Dexlansoprazole MR - A review

Annals of Medicine

Volumn 43, Issue 5, 2011, Pages 366-374

  Hershcovici, Tiberiu ^a   Jha, Lokesh K ^b   Fass, Ronnie ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Dexlansoprazole; dual delayed release formulation; gastroesophageal refl ux disease; heartburn; proton pump inhibitor

Indexed keywords

AMPICILLIN; DIAZEPAM; DIGOXIN; IRON; KETOCONAZOLE; LANSOPRAZOLE; PHENYTOIN; PLACEBO; TACROLIMUS; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FLATULENCE; HUMAN; NAUSEA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; DELAYED-ACTION PREPARATIONS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; MUCOUS MEMBRANE; PROTON PUMP INHIBITORS; STEREOISOMERISM;

EID: 79959326875     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.554429     Document Type: Review

References (35)

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-7. (Pubitemid 40559260)
2. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-56. (Pubitemid 27181367)
3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-6.
4. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)- an update. J Neurogastroenterol Motil. 2010;16:8-21.
5. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-11. (Pubitemid 34465190)
6. Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut. 2004; 53 Suppl 4:iv35-9. (Pubitemid 38580758)
7. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98(3 Suppl):S31-9. (Pubitemid 36348513)
8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-810. (Pubitemid 27240763)
9. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther. 2005;22: 79-94. (Pubitemid 41039696)
10. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol. 2010;26:389-94.
11. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.
12. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8. (Pubitemid 44383831)
13. Shin JM, Sachs G. Gastric H, K-ATPase as a drug target. Dig Dis Sci. 2006;51:823-33.
14. Hunt RH. Review article: the unmet needs in delayedrelease proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22 Suppl 3:10-19. (Pubitemid 41783982)
15. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010;26:367-78.
16. Horn JR, Howden CW. Review article: similarities and differences among delayedrelease proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22 Suppl 3:20-4. (Pubitemid 41783983)
17. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963-78. (Pubitemid 30618157)
18. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29:928-37.
19. Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S, et al. Determination of R(+ )- and S(+)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996;13:611-5. (Pubitemid 26119066)
20. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25: 627-38.
21. Metz DC, Howden CW, Perez MC, Larsen L, O'N eil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:742-54.
22. Zhang W, Wu J, Atkinson SN. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modifi ed-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology. 2007;132(suppl 52):A487.
23. Vakily M, Wu J, Atkinson SN, Mulford D. Population pharmacokinetics (PK) of TAK- 390MR in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). J Clin Pharmacol. 2008;48:1103.
24. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion. 1992;51 Suppl 1: 59-67.
25. Wu J, Vakily M, Witt G, Mulford D. TAK-390 MR vs. Lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%- time pH+ 4. Am J Gastroenterol. 2007;102(Suppl 2):124.
26. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor - evidence for dosing fl exibility. Aliment Pharmacol Ther. 2009;29:824-33.
27. Lee RD, Mulford D, Wu J, Atkinson SN. The effect of timeof- day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing fl exibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010;31:1001-11.
28. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modifi ed release (TAK-390MR), a proton pump inhibitor with a dual delayedrelease formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50.
29. Vakily M, Zhang W, Wu J, Mulford D. Effect of age and gender on the pharmacokinetics of a single oral dose of TAK- 390MR (modifi ed release) [abstract]. Clin Pharmacol Ther. 2008;83 Suppl 1:S96.
30. Lee RD, Wu J, Vakily M, Mulford D. Effect of hepatic impairment on the pharmacokinetics of TAK-390MR (modifi ed release) [abstract]. Clin Pharmacol Ther. 2008;2008(83 Suppl 1):S95.
31. Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731-41.
32. Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009;30:895-907.
33. Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261-72.
34. Mayer MD, Vakily M, Witt G, Mulford D. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis. Gastroenterology. 2008;134(4 Suppl1).
35. Vakily M, Wu J, Atkinson S. Effect of single oral doses (90 and 300 mg) of TAK-390MR on QT intervals [abstract]. Clin Pharmacol Ther. 2007;81(Suppl1).